VANCOUVER, Sept. 28, 2011 /CNW/ - Merus Labs International Inc. (the
"Company") is pleased to announce the implementation of a warrant
incentive program (the "Program"). Under the Program the Company will
grant to holders of its existing warrants one half of a bonus warrant
(a "Bonus Warrant") for each existing warrant exercised on or before
October 12, 2011. The Bonus Warrant is exercisable at $0.65 for 18
months. Existing warrants will be exercised in accordance with their
current terms. The Company has agreed to pay a 4% cash payment to
PowerOne Capital Markets Limited and Primary Capital in connection with
their assistance in having the existing warrant holders exercise their
warrants. It is a condition of the Program that minimum proceeds of
$4.5 million be raised in connection with the warrant exercise.
About Merus Labs International Inc.
Merus is a specialty pharmaceutical company engaged in the acquisition
and licensing of pharmaceutical products. The Company utilizes its
expertise in the North American pharmaceutical markets and its access
to capital to acquire and license niche branded products in Canada and
United States. Merus further enhances the sale and distribution of
these products by introduction of a focused marketing and promotion
This press release may contain forward-looking statements that involve
risks and uncertainties. These statements relate to future events or
our future financial performance. In some cases, you can identify
forward-looking statements by terminology including "could", "may",
"will", "should", "expect", "plan", "anticipate", "believe",
"estimate", "predict", "potential" and the negative of these terms or
other comparable terminology. While these forward-looking statements,
and any assumptions upon which they are based, are made in good faith
and reflect our current judgment regarding the direction of our
business, actual results will almost always vary, sometimes materially,
from any estimates, predictions, projections, assumptions or other
future performance suggested in this report. Except as required by
applicable law, we do not intend to update any of the forward-looking
statements so as to conform these statements to actual results.
Investors should refer to the risks disclosed in the Company's reports
filed from time to time with securities regulatory authorities.
SOURCE Merus Labs International Inc.
For further information:
Dr. Ahmad Doroudian, Chief Executive Officer
Merus Labs International Inc.
Tel: (604) 805-7783